Longeveron (LGVN) Q1 2026 earnings summary

Executive summary

• Strategic repositioning to a capital-efficient, asset-light model, emphasizing licensing partnerships for laromestrocel across four development programs targeting rare pediatric and age-related diseases.

• Completed a private placement in March 2026, raising $15.9 million and extending the cash runway into Q4 2026, but substantial doubt remains about the ability to continue as a going concern without further capital.

• No FDA-approved products; revenue is derived from clinical trial participation and contract manufacturing, both limited and declining.

• Participating in the BIO International Convention to explore global partnership opportunities.

• Appointment of Stephen H. Willard as CEO in February 2026 and implementation of cash-saving measures.

Financial highlights

• Q1 2026 revenues were $0.4 million, flat year-over-year; clinical trial revenue increased 46% while contract manufacturing revenue declined 84%.

• Net loss for Q1 2026 was $4.7 million, a 6% improvement from Q1 2025, driven by lower G&A and R&D expenses.

• General and administrative expenses decreased 7% to $2.7 million; R&D expenses decreased 8% to $2.3 million.

• Cash and cash equivalents stood at $15.8 million as of March 31, 2026, expected to fund operations into Q4 2026.

• Gross profit remained steady at $0.3 million for both Q1 2026 and Q1 2025.

Outlook and guidance

• Top-line results from the ELPIS II trial in HLHS are expected in August 2026, with immediate plans to engage the FDA for next steps.

• Preparation underway for a phase II registrational trial in pediatric dilated cardiomyopathy, with initiation targeted for 2027.

• Additional capital will be required to continue development and commercialization efforts beyond Q4 2026.

• Actively seeking strategic partnerships and non-dilutive funding, especially for the Alzheimer's program.

• Anticipates a pre-BLA meeting with the FDA in 2027, following submission of ELPIS II results and a full clinical study report.